(Beijing, Shanghai, Boston), November 11, 2025 -- Jacobio Pharma (1167.HK) is pleased to announce that the Company has been added to the MSCI China All Shares Small Cap Index, effective after market close on November 24, 2025 (subject to MSCI’s official announcement).
MSCI is a leading provider of equity indexes globally, widely used for asset allocation and benchmarking. As of July 2025, ETFs directly linked to MSCI equity indexes manage over USD 2 trillion in assets. The inclusion is expected to enhance Jacobio’s visibility in global capital markets and broaden its potential investor base among both index-tracking and actively managed funds.

About Jacobio Pharma
Jacobio Pharma (1167.HK) is committed to providing breakthrough treatments for patients. With an induced allosteric drug discovery platform, the company’s core projects focus on the KRAS pathway. The company envisions becoming a global leader in research and development, fostering strategic partnerships to drive innovation. Jacobio’s  R&D centers are in Beijing, Shanghai (China), and Boston (USA). Clinical trials are conducted at over 180 sites in China, more than 30 sites in the USA, and over 10 sites across several European countries.